These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 27050073)

  • 21. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B; Xing F; Wang J; Wang X; Zhou C; Fan G; Zhuo Q; Ji S; Yu X; Xu X; Qin Y; Li Z
    Cancer Lett; 2024 Oct; 602():217197. PubMed ID: 39216548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
    Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
    Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

  • 25. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
    Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
    Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
    J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
    Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
    EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
    Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
    Pham NA; Tsao MS; Cao P; Hedley DW
    Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
    Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
    Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
    An Y; Cai B; Chen J; Lv N; Yao J; Xue X; Tu M; Tang D; Wei J; Jiang K; Wu J; Li Q; Gao W; Miao Y
    Cancer Lett; 2013 Feb; 329(2):228-35. PubMed ID: 23178452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
    Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
    FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.